A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a Phase 1a/1b, first time in human (FTIH), open-label, dose escalation and expansion study to evaluate the safety, tolerability, and preliminary efficacy of CT-202 (study drug), a humanized T cell engaging bispecific antibody targeting nectin-4, in participants with nectin-4 expressing recurrent, unresectable or metastatic refractory/resistant TNBC, CRC, or UC. Results of the study including PK, PD, efficacy, and safety will be used in the RP2D determination.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Diagnoza zaawansowanego raka piersi (TNBC), raka jelita grubego lub raka pęcherza, który wcześniej był leczony standardowymi metodami
- •Guz mierzalny przy użyciu standardowych badań obrazowych
- •Ogólny stan zdrowia pozwalający na udział w badaniu (ECOG 0-2)
- •Spodziewana długość życia co najmniej 12 tygodni
- •Prawidłowe funkcjonowanie organów wewnętrznych
✗ Disqualifies
- •Historia poważnych powikłań skórnych z powodu poprzednich terapii
- •Nieskontrolowana aktywna infekcja lub inne warunki medyczne uniemożliwiające udział w badaniu
- •Jednoczesny udział w innym badaniu klinicznym
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 18, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
Tasman Oncology Research
Gold Coast, Australia
Calvary Mater Hospital Newcastle
Newcastle, Australia
Linear Clinical Research
Perth, Australia
Trial contact
Context Clinical Development
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/19/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.